Dr. Thomas Hutson, DO,PHARMD
What this data tells you about Dr. Hutson
Dr. Thomas Hutson is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Hutson performed 55,672 Medicare services across 2,351 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hutson received a total of $1,108,613 from 30 pharmaceutical and/or device companies across 821 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hutson is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 16,600 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 12,900 | $0 | $5 |
| Paclitaxel chemotherapy injection | 9,054 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 4,258 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,220 | $17 | $65 |
| Dexamethasone injection (steroid) | 2,066 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,140 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 800 | $0 | $24 |
| Comprehensive metabolic blood panel | 714 | $10 | $64 |
| Complete blood count (CBC) with differential | 691 | $8 | $36 |
| Blood draw (venipuncture) | 648 | $8 | $20 |
| Office visit, established patient (30-39 min) | 501 | $98 | $368 |
| Injection, leucovorin calcium, per 50 mg | 449 | $3 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 372 | $23 | $157 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 354 | $130 | $3,675 |
| Injection, fluorouracil, 500 mg | 306 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 301 | $102 | $707 |
| Injection of additional new drug or substance into vein | 271 | $12 | $108 |
| PSA test (prostate cancer screening) | 256 | $18 | $94 |
| Injection, carboplatin, 50 mg | 190 | $2 | $300 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 182 | $3 | $373 |
| Office visit, established patient (20-29 min) | 164 | $61 | $250 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 114 | $26 | $145 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 88 | $52 | $344 |
| Injection, magnesium sulfate, per 500 mg | 86 | $1 | $6 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 83 | $573 | $1,536 |
| Unclassified drugs | 67 | $1 | $8 |
| Administration of chemotherapy into vein, each additional hour | 64 | $23 | $161 |
| Injection, zoledronic acid, 1 mg | 60 | $7 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 59 | $49 | $313 |
| Infusion, normal saline solution , 1000 cc | 48 | $2 | $19 |
| Drug injection, under skin or into muscle | 43 | $11 | $96 |
| Ct scan of chest with contrast | 41 | $50 | $821 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 34 | $16 | $94 |
| CT scan of abdomen and pelvis with contrast | 33 | $176 | $1,067 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 33 | $135 | $500 |
| New patient office visit, complex (60-74 min) | 32 | $169 | $709 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $58 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 27 | $16 | $100 |
| Microscopic examination for white blood cells with manual cell count | 26 | $4 | $22 |
| Complete blood count (CBC), automated | 26 | $6 | $34 |
| Infusion into a vein for hydration, each additional hour | 26 | $10 | $75 |
| Administration of chemotherapy into vein using push technique | 24 | $81 | $500 |
| CT scan of chest, without contrast | 20 | $40 | $686 |
| Administration of additional new drug or substance into vein using push technique | 18 | $44 | $289 |
| Office visit, established patient, complex (40-54 min) | 17 | $142 | $496 |
| Reticulated (young) platelet measurement | 15 | $35 | $143 |
| Ct scan of abdomen and pelvis without contrast | 13 | $76 | $560 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 11 | $1,180 | $4,802 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Hutson is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Hutson experienced with pembrolizumab injection (keytruda)?
Does Dr. Hutson receive payments from pharmaceutical companies?
How do Dr. Hutson's costs compare to other medical oncologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology